UNSPSC 51171850: Prochlorperazine mesilate

This classification denotes a phenothiazine with the molecular formula C20H24ClN3S.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 531SH87H9N, chemically known as piperazine, 1-methyl-4-(3-(2-chloro-phenothiazin-10-yl)propyl)-, hydrogen methanesulfonate but generally known as prochlorperazine mesilate, which bears US NIH Compound Identifier 94252. European Medicines Agency schedules Prochlorperazine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04053MIG.

Most nations schedule prochlorperazine mesilate under HS 29343090 and SITC 51578. SMILES: Clc1cc2N(CCCN3CCN(CC3)C)c3c(Sc2cc1)cccc3.S(=O)(=O)(O)C.

UNSPSC 51171850 Prochlorperazine mesilate is a Commodity code that covers individual pharmaceutical products procured for use in state and local government health, corrections, and human services operations. Recent state and local activity shows this code being used to solicit pharmaceutical products and services that support offender health screening, pharmacy benefit management, and multi-source generic pharmaceutical distribution across correctional facilities, government employee health plans, and state health agencies. The issuing bodies include county correction departments, state health and human services commissions, and multistate cooperative purchasing alliances managing procurement on behalf of participating state and local entities. Work solicited under this code ranges from targeted pharmaceutical testing and screening support — as in offender specimen collection paired with drug testing — to broad generic pharmaceutical sourcing through cooperative purchasing vehicles that consolidate procurement across multiple jurisdictions and facility types.

Recent activity appears concentrated in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services, with proposals due July 23, 2026; the scope includes SAMHSA-certified lab testing at two collection sites in the Dallas area, with an estimated contract value of $600,000 over two years plus three optional one-year renewals. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in late March 2026 to explore direct-to-manufacturer pharmaceutical prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local facilities, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. Vendors serving this code must hold applicable lab certifications (SAMHSA, state pharmacy boards, or CAP), comply with FDA and Drug Supply Chain Security Act requirements, maintain substantial insurance coverage, and accept performance penalty structures tied to reporting timeliness and fulfillment accuracy.